10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
The inclusion and wording of a black box warning for thrombosis and embolism risk in the label for upadacitinib are now likely to be applied across all JAK inhibitors used for autoimmune diseases, according to SVB Leerink Research analyst Pasha Sarraf, referring to last Friday’s approval of AbbVie’s Rinvoq (upadacitinib) by the US Food and Drug Administration. 20 August 2019
Canada-headquartered Generex Biotechnology saw its shares rise 3.9% to $2.13 by mid-morning today, after it said that it has acquired an additional 38% of Olaregen Therapeutix for a total Generex ownership of approximately 99% after the share exchange at $2.50 a share for GNBT stock, in a cashless transaction. 18 August 2019
Discovered and developed by AbbVie Rinvoq (upadacitinib) marks the second US Food and Drug Administration approval of a targeted immunomodulator (TIM) therapy for the company this year. 17 August 2019
Celgene Corp today announced the US Food and Drug Administration has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. 16 August 2019
The Institute for Clinical and Economic Review (ICER) could scarcely have been more damning of two companies behind treatments for Duchenne muscular dystrophy (DMD), the most common fatal genetic disease diagnosed in childhood. 16 August 2019
Ultra-rare disease specialist Ultragenyx Pharmaceutical has inked a deal with GeneTx Biotherapeutics in relation to the antisense oligonucleotide GTX-102. 16 August 2019
GeneCentric Therapeutics has acquired the data analysis and biomarker development firm Select ImmunoGenomics. Both companies are based in North Carolina, USA. 16 August 2019
The US Food and Drug Administration has granted accelerated approval for Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). 16 August 2019
Eli Lilly has released data showing that its Taltz (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study, which evaluated the efficacy and safety of Taltz versus rival drug Tremfya (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). 15 August 2019
Two senior executives at Novartis' AveXis unit are being shown the door as the firm faces accusations from the US regulator it was aware of data manipulation before it filed for gene therapy Zolgensma (onasemnogene abeparvovec-xioi). 15 August 2019
Australian biotech CSL Limited saw its shares rise 6.6% to A$234.00 today, after it posted revenue of $8,539 million, up 7.9%, for the 12 months ended June 30, 2019. CSL is Australia largest health business specializing in immunotherapies and vaccines for life-threatening diseases. 14 August 2019
A week after presenting compelling Lynparza (olaparib) results in prostate cancer, AstraZeneca and Merck & Co have completed the data set in support of its use across advanced ovarian cancer disease maintenance settings. 14 August 2019
Adding to good previous earlier-stage clinical data, Regeneron Pharmaceuticals today announced positive pivotal Phase III results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH). 14 August 2019
Danish dermatology specialist LEO Pharma says it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the European Union and Siliq in other regions) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licensing agreement with Bausch Health. 14 August 2019
If the accusation of withholding information over Zolgensma (onasemnogene abeparvovec-xioi) is the first major test for Novartis chief executive Vasant Narasimhan, then it is increasingly looking like a big one. 14 August 2019
The US Food and Drug Administration has granted Breakthrough Therapy designation (BTD) for Calquence (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. 14 August 2019
China’s medicines regulator has called for greater implementation of the Vaccine Administration Law, urging drug regulatory departments to put promoting awareness of the law “at the top of their agenda.” 13 August 2019
A resounding success in the Phase III INVICTUS study sent shares in East Coast, USA-based Deciphera Pharmaceuticals climbing around 80% on Tuesday. 13 August 2019
The Janssen and AbbVie partnered drug Imbruvica (ibrutinib) has now nabbed five European Commission (EC) approvals in as many years, as its use was broadened in two indications. 13 August 2019
Positive growth from tablet products propelled allergy immunotherapy specialist ALK Abello to a strong performance in the second quarter of 2019, with total revenues up 9% at 785 million Danish kroner ($117 million). 13 August 2019